Involvement of reactive oxygen species in 2-methoxyestradiol-induced apoptosis in human neuroblastoma cells

Cancer Letters

Volumn 313, Issue 2, 2011, Pages 201-210

  Zhang, Qi ^a   Ma, Yan ^a   Cheng, Yue Fang ^a   Li, Wen Jie ^a   Zhang, Zhenzhong ^a   Chen, Shao yu ^b  

^a ZHENGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

2 Methoxyestradiol; Apoptosis; Neuroblastoma; Reactive oxygen species

Indexed keywords

2 METHOXYESTRADIOL; ANTIOXIDANT; APOPTOSIS INDUCING FACTOR; ASCORBIC ACID; CASPASE 3; CASPASE 9; GLUTATHIONE; MITOQ10; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUROBLASTOMA CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; UPREGULATION;

ANTIOXIDANTS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; ESTRADIOL; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEUROBLASTOMA; ORGANOPHOSPHORUS COMPOUNDS; REACTIVE OXYGEN SPECIES; UBIQUINONE;

EID: 82655187480     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.09.005     Document Type: Article

References (54)

1. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 2003, 3:203-216.
2. Goldsby R.E., Matthay K.K. Neuroblastoma: evolving therapies for a disease with many faces. Paediatr. Drugs 2004, 6:107-122.
3. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
4. De Bernardi B., Nicolas B., Boni L., Indolfi P., Carli M., Cordero Di Montezemolo L., Donfrancesco A., Pession A., Provenzi M., di Cataldo A., Rizzo A., Tonini G.P., Dallorso S., Conte M., Gambini C., Garaventa A., Bonetti F., Zanazzo A., D'Angelo P., Bruzzi P. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J. Clin, Oncol. 2003, 21:1592-1601.
5. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeur G.M., Gerbing R.B., Reynolds C.P. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's cancer group. N Engl. J. Med. 1999, 341:1165-1173.
6. Sawada T., Kidowaki T., Sakamoto I., Hashida T., Matsumura T., Nakagawa M., Kusunoki T. Neuroblastoma. Mass screening for early detection and its prognosis. Cancer 1984, 53:2731-2735.
7. Nishi M., Miyake H., Takeda T., Shimada M., Takasugi N., Sato Y., Hanai J. Effects of the mass screening of neuroblastoma in Sapporo City. Cancer 1987, 60:433-436.
8. Zhu B.T., Conney A.H. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis?. Cancer Res. 1998, 58:2269-2277.
9. Pribluda V.S., Gubish E.R., Lavallee T.M., Treston A., Swartz G.M., Green S.J. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis. Rev. 2000, 19:173-179.
10. Fotsis T., Zhang Y., Pepper M.S., Adlercreutz H., Montesano R., Nawroth P.P., Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994, 368:237-239.
11. Mooberry S.L. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr. Opin. Oncol. 2003, 15:425-430.
12. Dubey R.K., Jackson E.K. Potential vascular actions of 2-methoxyestradiol. Trends Endocrinol. Metab. 2009, 20:374-379.
13. Fotopoulou C., Baumunk D., Schmidt S.C., Schumacher G. Additive growth inhibition after combined treatment of 2-methoxyestradiol and conventional chemotherapeutic agents in human pancreatic cancer cells. Anticancer. Res. 2010, 30:4619-4624.
14. Kulke M.H., Chan J.A., Meyerhardt J.A., Zhu A.X., Abrams T.A., Blaszkowsky L.S., Regan E., Sidor C., Fuchs C.S. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother. Pharmacol. 2010.
15. Miller V.M. Estrogen metabolomics: a physiologist's perspective. Hypertension 2010, 56:816-818.
16. Pelicano H., Carney D., Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updates 2004, 7:97-110.
17. Schumacker P.T. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006, 10:175-176.
18. Waris G., Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J. Carcinog 2006, 5:14.
19. Hildeman D.A., Mitchell T., Aronow B., Wojciechowski S., Kappler J., Marrack P. Control of Bcl-2 expression by reactive oxygen species. Proc. Natl. Acad. Sci. USA 2003, 100:15035-15040.
20. Huang P., Feng L., Oldham E.A., Keating M.J., Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000, 407:390-395.
21. Kachadourian R., Liochev S.I., Cabelli D.E., Patel M.N., Fridovich I., Day B.J. 2-methoxyestradiol does not inhibit superoxide dismutase. Arch. Biochem. Biophys. 2001, 392:349-353.
22. Sattler M., Quinnan L.R., Pride Y.B., Gramlich J.L., Chu S.C., Even G.C., Kraeft S.K., Chen L.B., Salgia R. 2-methoxyestradiol alters cell motility, migration, and adhesion. Blood 2003, 102:289-296.
23. Fajardo I., Quesada A.R., Nunez de Castro I., Sanchez-Jimenez F., Medina M.A. A comparative study of the effects of genistein and 2-methoxyestradiol on the proteolytic balance and tumour cell proliferation. Brit. J. Cancer 1999, 80:17-24.
24. Manca P., Chisu V. 2-methoxyestradiol induces morpho-functional changes and impairs the microtubular system in mouse neuroblastoma and rat glioma cells. Arch. Ital. Biol. 2010, 148:11-21.
25. Wassberg E. Angiostatic treatment of neuroblastoma. Upsala J. Med. Sci. 1999, 104:1-24.
26. Nakagawa-Yagi Y., Ogane N., Inoki Y., Kitoh N. The endogenous estrogen metabolite 2-methoxyestradiol induces apoptotic neuronal cell death in vitro. Life Sci. 1996, 58:1461-1467.
27. Pan J., She M., Xu Z.X., Sun L., Yeung S.C. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res. 2005, 65:3671-3681.
28. Pani G., Colavitti R., Bedogni B., Fusco S., Ferraro D., Borrello S., Galeotti T. Mitochondrial superoxide dismutase: a promising target for new anticancer therapies. Curr. Med. Chem. 2004, 11:1299-1308.
29. Atsumi T., Tonosaki K., Fujisawa S. Comparative cytotoxicity and ROS generation by curcumin and tetrahydrocurcumin following visible-light irradiation or treatment with horseradish peroxidase. Anticancer Res. 2007, 27:363-371.
30. Meng L.H., Ding J. Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation. Acta Pharmacol. Sin. 2007, 28:1460-1465.
31. Benhar M., Dalyot I., Engelberg D., Levitzki A. Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol. Cell. Biol. 2001, 21:6913-6926.
32. Asumendi A., Morales M.C., Alvarez A., Arechaga J., Perez-Yarza G. Implication of mitochondria-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl)retinamide-induced apoptosis. Brit. J. Cancer 2002, 86:1951-1956.
33. Lin H.L., Liu T.Y., Chau G.Y., Lui W.Y., Chi C.W. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 2000, 89:983-994.
34. Mates J.M., Sanchez-Jimenez F.M. Role of reactive oxygen species in apoptosis: implications for cancer therapy. Int. J. Biochem. Cell Biol. 2000, 32:157-170.
35. She M.R., Li J.G., Guo K.Y., Lin W., Du X., Niu X.Q. Requirement of reactive oxygen species generation in apoptosis of leukemia cells induced by 2-methoxyestradiol. Acta Pharmacol. Sin. 2007, 28:1037-1044.
36. Zhou Y., Hileman E.O., Plunkett W., Keating M.J., Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003, 101:4098-4104.
37. Chauhan D., Catley L., Hideshima T., Li G., Leblanc R., Gupta D., Sattler M., Richardson P., Schlossman R.L., Podar K., Weller E., Munshi N., Anderson K.C. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood 2002, 100:2187-2194.
38. Gao N., Rahmani M., Dent P., Grant S. 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene 2005, 24:3797-3809.
39. Lin H.L., Liu T.Y., Wu C.W., Chi C.W. 2-Methoxyestradiol-induced caspase-3 activation and apoptosis occurs through G(2)/M arrest dependent and independent pathways in gastric carcinoma cells. Cancer 2001, 92:500-509.
40. Ting C.M., Lee Y.M., Wong C.K., Wong A.S., Lung H.L., Lung M.L., Lo K.W., Wong R.N., Mak N.K. 2-Methoxyestradiol induces endoreduplication through the induction of mitochondrial oxidative stress and the activation of MAPK signaling pathways. Biochem. Pharmacol. 2010, 79:825-841.
41. Chua Y.S., Chua Y.L., Hagen T. Structure activity analysis of 2-methoxyestradiol analogues reveals targeting of microtubules as the major mechanism of antiproliferative and proapoptotic activity. Mol. Cancer Ther. 2010, 9:224-235.
42. Gao N., Rahmani M., Shi X., Dent P., Grant S. Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress. Blood 2006, 107:241-249.
43. Djavaheri-Mergny M., Wietzerbin J., Besancon F. 2-Methoxyestradiol induces apoptosis in Ewing sarcoma cells through mitochondrial hydrogen peroxide production. Oncogene 2003, 22:2558-2567.
44. Guessous I., Cornuz J., Paccaud F. Lung cancer screening: current situation and perspective. Swiss Med. Wkly. 2007, 137:304-311.
45. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998, 281:1309-1312.
46. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nat. Med. 2000, 6:513-519.
47. Attalla H., Westberg J.A., Andersson L.C., Adlercreutz H., Makela T.P. 2-Methoxyestradiol-induced phosphorylation of Bcl-2: uncoupling from JNK/SAPK activation. Biochem. Biophys. Res. Commun. 1998, 247:616-619.
48. Gao Z., Shao Y., Jiang X. Essential roles of the Bcl-2 family of proteins in caspase-2-induced apoptosis. J. Biol. Chem. 2005, 280:38271-38275.
49. Antonsson B., Conti F., Ciavatta A., Montessuit S., Lewis S., Martinou I., Bernasconi L., Bernard A., Mermod J.J., Mazzei G., Maundrell K., Gambale F., Sadoul R., Martinou J.C. Inhibition of Bax channel-forming activity by Bcl-2. Science 1997, 277:370-372.
50. Lambert C., Apel K., Biesalski H.K., Frank J. 2-methoxyestradiol induces caspase-independent, mitochondria-centered apoptosis in DS-sarcoma cells. Int. J. Cancer 2004, 108:493-501.
51. 10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 2009, 54:322-328.
52. James A.M., Cocheme H.M., Smith R.A., Murphy M.P. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J. Biol. Chem. 2005, 280:21295-21312.
53. Murphy M.P., Smith R.A. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv. Drug. Deliv. Rev. 2000, 41:235-250.
54. Smith R.A., Porteous C.M., Gane A.M., Murphy M.P. Drug delivery to mitochondria: the key to mitochondrial medicine, delivery of bioactive molecules to mitochondria in vivo. Proc. Natl. Acad. Sci. USA 2003, 100:5407-5412.